EP3412313A1 - Temperature sensitive hydrogel composition including nucleic acid and chitosan - Google Patents
Temperature sensitive hydrogel composition including nucleic acid and chitosan Download PDFInfo
- Publication number
- EP3412313A1 EP3412313A1 EP16889476.4A EP16889476A EP3412313A1 EP 3412313 A1 EP3412313 A1 EP 3412313A1 EP 16889476 A EP16889476 A EP 16889476A EP 3412313 A1 EP3412313 A1 EP 3412313A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- temperature
- chitosan
- nucleic acid
- sensitive hydrogel
- hydrogel composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 98
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 86
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 78
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 78
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 239000011550 stock solution Substances 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 23
- 229920002674 hyaluronan Polymers 0.000 claims description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 102000053602 DNA Human genes 0.000 claims description 18
- 239000007853 buffer solution Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 239000002861 polymer material Substances 0.000 claims description 7
- 229920002477 rna polymer Polymers 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 229920002125 SokalanĀ® Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 abstract description 33
- 238000001879 gelation Methods 0.000 abstract description 13
- 230000007704 transition Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 27
- 229920000642 polymer Polymers 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 6
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 6
- 229920000447 polyanionic polymer Polymers 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- -1 poly(vinylalcohol) Polymers 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011557 critical solution Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2377/00—Characterised by the use of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Derivatives of such polymers
- C08J2377/04—Polyamides derived from alpha-amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Definitions
- the present invention relates to a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
- a hydrogel is a polymer structure having a three-dimensional network structure containing a water phase (Rohindra D.R. et al., 2004), and the hydrogel is formed by covalent binding or non-covalent binding between hydrophilic polymers (Hwang June-seok, et al., 2008).
- the hydrogel composed of various hydrophilic polymers has a high moisture content, leading to excellent biocompatibility, and thus many studies have been made for the application thereof as a biomaterial.
- Hydrogels sensitive to stimuli such as pH, temperature, electric field, magnetic field, light, and ultrasonic waves, may be especially used in drug delivery systems allowing the controlled release according to the absence or presence of stimuli (Hoffman A.S., 2002).
- temperature-sensitive hydrogels are most widely studied in cell carriers and drug delivery systems for tissue regeneration.
- the reason is that many polymers exhibit temperature transition characteristics. Therefore, when a hydrophilic group capable of dissolving or swelling general polymers in water is introduced, the corresponding polymers are dissolved or swollen in water and thus the solubility of the polymers in water increases as the temperature increases, but the polymers composed of a hydrophilic portion and a hydrophobic portion, such as methyl, ethyl, and propyl, have a lower critical solution temperature (LCST) at which the solubility in water decreases as the temperature increases, and thus the polymers are condensed to form a gel when the temperature increases (Ward M.A. et al., 2011).
- LCST critical solution temperature
- a polymer composed of hydrophilic and hydrophobic portions is dissolved in water to become a sol state since the hydrogen bonding strength between the hydrophilic group of the polymer and a water molecule is strong, but when the temperature is increased, the binding strength between the hydrophobic group portions of the polymer is stronger than the hydrogen bonding strength, and thus the hydrophobic group portion of the polymer agglomerates to cause phase transition into a gel state.
- this polymer solution is in a sol state, such as a fluid, at a general temperature
- the mixing with a drug is allowable through simple mixing
- a heat having a temperature equal to or higher than the body temperature is applied to the polymer solution
- the polymer solution forms a gel, allowing a sustained release of a drug.
- a polymer needs to be released out of the human body through the metabolism of the human body after being used in the human body. Therefore, it is important that temperature-sensitive hydrogels for medical or human application exhibit biocompatibility and biodegradability.
- the reaction concentrations of the compositions are higher in the temperature-sensitive hydrogels shown by hydrophobic-hydrophilic linkage.
- a high reaction concentration cannot only influence the human body by the injection of hydrogels into the human body, but also influence the degradation rates in the human body. Therefore, the development of hydrogels capable of exhibiting temperature sensitivity even at low concentrations can help developing safer biocompatible substances.
- the polymers constituting hydrogels include: natural polymers, such as chitosan (Berger J. et al., 2004), alginate (Augst A.D. et al., 2006), dextran, hyaluronic acid, gelatin, and collagen; and synthetic polymers, such as poly(vinylalcohol) (Bodugoz-Senturk H., et al., 2009), polyethyleneimine (Jin R.H. et al., 2005), and poly(ethylene glycol) (Mahoney M.J. et al., 2006).
- natural polymers such as chitosan (Berger J. et al., 2004), alginate (Augst A.D. et al., 2006), dextran, hyaluronic acid, gelatin, and collagen
- synthetic polymers such as poly(vinylalcohol) (Bodugoz-Senturk H., et al
- Chitosan may be produced by deacetylation of chitin, which is a natural polysaccharide in a ā -(1 ā 4)-linked form of N-acetyl-D-glucosamine that can be obtained from cellular walls of crustaceans, such as crab, general shrimp, and lobster; mollusks such as cuttlefish; insects; and bacteria. Chitosan is easily dissolved in an inorganic acid aqueous solution, and thus is utilized in various fields, such as coagulants for wastewater treatment, heavy metal adsorbents, foods, and cosmetics.
- chitin is a natural polysaccharide in a ā -(1 ā 4)-linked form of N-acetyl-D-glucosamine that can be obtained from cellular walls of crustaceans, such as crab, general shrimp, and lobster; mollusks such as cuttlefish; insects; and bacteria.
- Chitosan is easily dissolved in an inorganic acid aqueous solution, and thus is utilized
- chitosan is a polysaccharide obtained from natural materials, and it has been reported that chitosan has excellent biocompatibility and biodegradability, cell association, biological tissue culture, and biological activities, such as antibacterial, aromatic, non-toxic, and hemostatic properties (Park Jun-gyu et al., 2015).
- nucleic acids which have been recognized as a genome to store and deliver genetic information, are distributed around the diseased tissue to promote cell growth and differentiation and angiogenesis and perform an inflammation inhibitory function. That is, nucleic acids are degraded into small fragments outside cells and bind to receptors on the cell surface to stimulate signals into the cells.
- Hydrogels composed of DNA have very excellent biocompatibility, and thus are medically studied in various fields.
- the production results of functional DNA hydrogels that respond to heat and enzymes to induce free degradation and re-association have been recently reported (Xing Y. et al., 2011). Therefore, side effects due to overdosing of drugs can be reduced by enabling a smart drug delivery method in which drugs are allowed to flow only in case of necessity.
- DNA hydrogels are composed of biomaterial DNA, and thus are not harmful to the human body, so the DNA hydrogels can be used as artificial tissues for wounded sites with various shapes and can be variously applied as an effective drug carrier in a medical field.
- nucleic acids are easily degraded by degradation enzymes existing in the human body, so that the in vivo residence of nucleic acids for application of the nucleic acids to target disease tissues is low, resulting in a lack of drug persistence, and in the case where DNA hydrogels are utilized, the degradation of the nucleic acids by degradation enzymes causes a collapse of structures, and thus the DNA hydrogels may not properly perform as roles of artificial tissues and drug carriers (Lee Jong-beom, et al., 2012). Therefore, it is necessary to conduct research to enhance the drug persistence of nucleic acids and to solve the problems of DNA hydrogels.
- the present inventors conducted continuous research in order to prepare a temperature-sensitive hydrogel, which exists in a sol state at room temperature and forms a gel when injected into the body, and as a result, the present inventors produced a temperature-sensitive hydrogel with biocompatibility and biodegradability through a combination of chitosan and a nucleic acid, and thus completed the present invention.
- Korean Patent Publication No. 2014-0090670 as a prior art discloses an in-situ crosslinkable polymer composition, but never states temperature sensitivity and hydrogels.
- the crosslinkable polymer composition of this patent publication contains about 0.1 wt% to about 95 wt% of more than one kind of polyanionic polymer, about 0.1 wt% to about 90 wt% of more than one kind of polycationic polymer, and 0.1 wt% to 99.8 wt% of water, and thus this polymer composition is different from a temperature-sensitive hydrogel composition of the present invention in view of the mixing ratio.
- the patent publication discloses that the polyanions include crosslinkable and non-crosslinkable polyanions, and a polynucleotide is suggested as one of the non-crosslinkable polyanion components.
- the patent publication discloses that the non-crosslinkable polyanions are further included in the polyanions, and it can be seen that the non-crosslinkable anions do not influence crosslinkage.
- a temperature-sensitive hydrogel of the present invention is formed through a non-crosslinkage between a nucleic acid and chitosan, and thus it can be seen that the temperature-sensitive hydrogel of the present invention is different from the polymer composition in the patent publication in view of the constituent elements.
- European Publication Patent No. 2745849 discloses a combination of polydeoxyribonucleotide (PDRN) and chitosan but does not state a temperature-sensitive hydrogel, wherein the combination contains 0.002-0.25 wt% of polydeoxyribonucleotide and 1-10 wt% of chitosan, which is different from the constitution of the present invention.
- PDRN polydeoxyribonucleotide
- chitosan which is different from the constitution of the present invention.
- US Patent Publication No. 2015-0111834 discloses an in-situ gel composition, wherein an anti-gelation agent is introduced for prevention of gelation at room temperature, and thus it can be seen that the in-situ gel composition is different from the constitution of the present invention.
- An aspect of the present invention is to provide a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
- a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, wherein the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1.
- the present invention may be a temperature-sensitive hydrogel composition wherein the weight ratio of a nucleic acid and chitosan is preferably 50:1 to 2000:1 and most preferably 100:1 to 1000:1.
- the content of the nucleic acid may be 0.01 wt% to 3 wt% relative to the total weight of the composition.
- the nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
- the content of the chitosan may be 1x10 -6 wt% to 0.15 wt% relative to the total weight of the composition.
- the molecular weight of the chitosan may be 3 kDa to 1000 kDa.
- the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient.
- the polymer material may be at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof.
- a method for producing the temperature-sensitive hydrogel composition including: i) preparing a nucleic acid stock solution; ii) preparing a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of a nucleic acid and chitosan is 20:1 to 10000:1, followed by stirring; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- the method may include: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and vi) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- the temperature-sensitive hydrogel composition may have an osmotic pressure of 100-500 mOsm and a pH value of 6-8.
- the temperature-sensitive hydrogel refers to a hydrogel of which a phase transition occurs from a sol into a gel or a gel into a sol according to the temperature.
- a transition of a sol into a gel is referred to as gelation.
- the gelation in the present invention is defined by a state in which a polymer having viscoelasticity forms a three-dimensional network structure with increasing temperature, and thus remains without being dissolved in a solvent.
- the sol-gel transition temperature thereof may vary according to the mixing ratio of a nucleic acid and chitosan, and here, the sol-gel transition temperature can be adjusted by changing the mixing ratio according to the purpose for use.
- the temperature-sensitive hydrogel composition containing a nucleic acid and chitosan is highly stable in which a homogeneous state is maintained and the layer separation does not occur.
- the weight ratio of the nucleic acid and the chitosan is in the range of preferably 20:1 to 10000:1, more preferably 50:1 to 2000:1, and most preferably 100:1 to 1000:1.
- the content of the nucleic acid may be 0.01-3 wt%, preferably 0.1-2 wt%, and most preferably 1-1.5 wt% relative to the total weight of the composition.
- the molecular weight of the nucleic acid may be 1-100,000 kDa, preferably 10-10,000 kDa, and most preferably 50-3,500 kDa.
- the nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
- the nucleic acid may be deoxyribonucleic acid.
- the deoxyribonucleic acid may include oligonucleotides, polynucleotides, and polydeoxyribonucleotides (PDRN).
- PDRN polydeoxyribonucleotides
- the nucleic acid may form a hydrogel through a combination with chitosan, and can act as a therapeutic drug in the body.
- the content of chitosan may be 1x10 -6 wt% to 0.15 wt%, preferably 1x10 -5 wt% to 0.1 wt%, and most preferably 1x10 -4 wt% to 0.075 wt%, relative to the total weight of the composition.
- the molecular weight of chitosan is 3 kDa to 1000 kDa, but is not limited thereto.
- the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient, wherein the polymer material may be added to make secure the adjustment of physical property changes according to the use of the temperature-sensitive hydrogel containing the nucleic acid and chitosan.
- the polymer material may employ at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof, but is not limited thereto.
- the temperature-sensitive hydrogel composition may be used for a medical use and as a cosmetic agent.
- a method for producing the temperature-sensitive hydrogel includes: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- the buffer solution that can be used in the preparation of the nucleic acid stock solution may employ sodium phosphate dibasic dodecahydrate, sodium chloride, magnesium chloride, potassium chloride, phosphate buffer saline, or HEPES (N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid) buffer solution, and preferably sodium phosphate dibasic dodecahydrate, but is not limited thereto.
- the acidic buffer that can be used in the preparation of the chitosan stock solution may employ acetic acid, hydrochloric acid, ascorbic acid, lactic acid, and nitric acid, and preferably acetic acid, but is not limited thereto.
- the mixing of the nucleic acid and the chitosan is conducted such that the weight ratio of nucleic acid and chitosan is 20:1 to 10000:1, and here, the content of the nucleic acid is 0.01-3 wt% relative to the total weight of the composition, and the content of the chitosan is 1x10 -6 wt% to 0.15 wt% relative to the total weight of the composition.
- the osmotic pressure and pH thereof may be adjusted so that the composition can be injected into the human body or coated on the skin.
- the production method may further include a step of adjusting pH in step iv).
- the osmotic pressure of the temperature-sensitive hydrogel composition obtained by the production method may be 100-500 mOsm, preferably 150-450 mOsm, and most preferably 200-400 mOsm.
- the pH of the temperature-sensitive hydrogel composition obtained by the production method may be 6-8, preferably 6.5-7.5, and most preferably 7.
- the present invention provides a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
- the hydrogel has excellent biocompatibility and biostability and exhibits a sol-gel transition property according to the temperature change, so that the hydrogel exists in a sol state at room temperature, and the hydrogel is gelated when the hydrogel has a high temperature by being injected into the body or coated on the epidermal skin surface.
- the temperature-sensitive hydrogel of the present invention can be directly injected and coated on a particular site in needed of therapy, and can increase the time for drug persistence and drug attachment through the gelation according to the temperature, and thus the drug efficacy thereof can sufficiently exerted. Therefore, the temperature-sensitive hydrogel is expected to be utilized in various therapies.
- nucleic acid and chitosan hydrogels were prepared with concentrations corresponding examples shown in table 1 below.
- nucleic acid was put in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate, and then dissolved therein using a heat stirrer at 65Ā°C for 1 hour.
- chitosan was dissolved using 100 mM acetic acid.
- nucleic acid and chitosan stock solutions prepared with the concentrations in table 1 below were mixed at a weight ratio of 1:1, and stirred in a heat stirrer at 60Ā°C for 1 hour. Thereafter, the temperature was lowered to room temperature, followed by stirring for 1 hour, to produce nucleic acid-chitosan hydrogels.
- a nucleic acid-chitosan-hyaluronic acid hydrogel was produced through the following procedure.
- a nucleic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2.2 wt%.
- the nucleic acid were dissolved using a heat stirrer at 65Ā°C for 1 hour.
- chitosan was dissolved in 100 mM acetic acid to have a concentration of 0.4 wt%.
- Sodium hyaluronic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2 wt%.
- the sodium hyaluronic acid was dissolved using a heat stirrer at 40Ā°C for 30 minutes, followed by cooling to room temperature with stirring using a stirrer.
- nucleic acid-chitosan-hyaluronic acid hydrogels of example 2 2.2 wt% of the prepared nucleic acid solution and 0.4 wt% of the prepared chitosan solution were mixed at a weight ratio of 9:1, followed by stirring in a heat stirrer at 65Ā°C for 10 minutes. 2 wt% of sodium hyaluronic acid was added to the nucleic acid-chitosan mixture solution at a weight ratio of 1:1, followed by stirring in a heat stirrer at 65Ā°C for 1 hour, and then the resulting solution was cooled to room temperature while the stirring maintained, thereby producing nucleic acid-chitosan-hyaluronic acid hydrogels of example 2.
- Chitosan was dissolved using 100 mM acetic acid.
- hydrogel compositions of example 1, example 2, comparative example 1, and comparative example 2 were used to investigate gelation, gel stability, and solubility thereof.
- composition was subjected to mixing, and then the transparency and gelation state thereof were observed to the naked eye for 3 days.
- the gelation was examined by viscoelasticity and the gel stability was examined by precipitate generation and layer separation.
- the hydrogel composition of each of example 1, example 2, comparative example 1, and comparative example 2 was dropped in an aqueous solution at 37.5Ā°C, followed by gelation, and then the solubility of gel was examined while the stirring was conducted at 400 rpm for 5 minutes with the temperature maintained at 37.5Ā°C.
- the results were shown in table 3 and FIGS. 1 and 2 .
- the hydrogel composition of the present invention shows temperature sensitivity, high stability, and a gel form continuously maintained after gelation, and here, it was confirmed that the weight ratio of nucleic acid and chitosan plays a key role.
- the temperature-sensitive hydrogel composition produced in each of example 1, example 2, comparative example 1, and comparative example 2 was examined for sol-gel transition.
- a rheometer was used for the confirmation of sol-gel transition.
- the measurement conditions used here were PU20, gap of 0.5 mm, 0.1 Hz, and 1% stress-strain, and the changes of G' (elasticity) and G" (viscosity) were measured while the temperature was raised from 24Ā°C to 40Ā°C by 1Ā°C and then was maintained for 1 minute.
- G' elasticity
- G" viscosity
- the temperature-sensitive hydrogel of example 1-3 exhibited a gentle decrease width of G' (elasticity) and an increase of G" (viscosity) with an increasing temperature ( FIG. 3A ), which correspond to the feature of a temperature-sensitive hydrogel.
- the temperature-sensitive hydrogel of example 1-3 exhibited a sol state at a temperature lower than 36Ā°C but was gelated at a temperature exceeding 36Ā°C ( FIG. 3B ). It was confirmed that these results were identical in all of the temperature-sensitive hydrogel compositions in examples 1 and 2. It can be seen from these results that the hydrogel compositions of the present invention show temperature sensitivity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
- A hydrogel is a polymer structure having a three-dimensional network structure containing a water phase (Rohindra D.R. et al., 2004), and the hydrogel is formed by covalent binding or non-covalent binding between hydrophilic polymers (Hwang June-seok, et al., 2008). The hydrogel composed of various hydrophilic polymers has a high moisture content, leading to excellent biocompatibility, and thus many studies have been made for the application thereof as a biomaterial. Hydrogels sensitive to stimuli, such as pH, temperature, electric field, magnetic field, light, and ultrasonic waves, may be especially used in drug delivery systems allowing the controlled release according to the absence or presence of stimuli (Hoffman A.S., 2002).
- Of these, temperature-sensitive hydrogels are most widely studied in cell carriers and drug delivery systems for tissue regeneration. The reason is that many polymers exhibit temperature transition characteristics. Therefore, when a hydrophilic group capable of dissolving or swelling general polymers in water is introduced, the corresponding polymers are dissolved or swollen in water and thus the solubility of the polymers in water increases as the temperature increases, but the polymers composed of a hydrophilic portion and a hydrophobic portion, such as methyl, ethyl, and propyl, have a lower critical solution temperature (LCST) at which the solubility in water decreases as the temperature increases, and thus the polymers are condensed to form a gel when the temperature increases (Ward M.A. et al., 2011). That is, a polymer composed of hydrophilic and hydrophobic portions is dissolved in water to become a sol state since the hydrogen bonding strength between the hydrophilic group of the polymer and a water molecule is strong, but when the temperature is increased, the binding strength between the hydrophobic group portions of the polymer is stronger than the hydrogen bonding strength, and thus the hydrophobic group portion of the polymer agglomerates to cause phase transition into a gel state.
- In the case where this polymer solution is in a sol state, such as a fluid, at a general temperature, the mixing with a drug is allowable through simple mixing, and in the case where a heat having a temperature equal to or higher than the body temperature is applied to the polymer solution, the polymer solution forms a gel, allowing a sustained release of a drug. However, such a polymer needs to be released out of the human body through the metabolism of the human body after being used in the human body. Therefore, it is important that temperature-sensitive hydrogels for medical or human application exhibit biocompatibility and biodegradability.
- As for the content of the temperature-sensitive hydrogel composition, which has been studied until now, it can be seen that the reaction concentrations of the compositions are higher in the temperature-sensitive hydrogels shown by hydrophobic-hydrophilic linkage. A high reaction concentration cannot only influence the human body by the injection of hydrogels into the human body, but also influence the degradation rates in the human body. Therefore, the development of hydrogels capable of exhibiting temperature sensitivity even at low concentrations can help developing safer biocompatible substances.
- The polymers constituting hydrogels include: natural polymers, such as chitosan (Berger J. et al., 2004), alginate (Augst A.D. et al., 2006), dextran, hyaluronic acid, gelatin, and collagen; and synthetic polymers, such as poly(vinylalcohol) (Bodugoz-Senturk H., et al., 2009), polyethyleneimine (Jin R.H. et al., 2005), and poly(ethylene glycol) (Mahoney M.J. et al., 2006).
- Chitosan may be produced by deacetylation of chitin, which is a natural polysaccharide in a Ī²-(1ā4)-linked form of N-acetyl-D-glucosamine that can be obtained from cellular walls of crustaceans, such as crab, general shrimp, and lobster; mollusks such as cuttlefish; insects; and bacteria. Chitosan is easily dissolved in an inorganic acid aqueous solution, and thus is utilized in various fields, such as coagulants for wastewater treatment, heavy metal adsorbents, foods, and cosmetics. In addition, chitosan is a polysaccharide obtained from natural materials, and it has been reported that chitosan has excellent biocompatibility and biodegradability, cell association, biological tissue culture, and biological activities, such as antibacterial, aromatic, non-toxic, and hemostatic properties (Park Jun-gyu et al., 2015).
- It is known that nucleic acids, which have been recognized as a genome to store and deliver genetic information, are distributed around the diseased tissue to promote cell growth and differentiation and angiogenesis and perform an inflammation inhibitory function. That is, nucleic acids are degraded into small fragments outside cells and bind to receptors on the cell surface to stimulate signals into the cells.
- As for still another type of research, studies are being actively conducted in various fields, such as making very elaborate nanostructures using a self-assembly property inherent to nucleic acids. Since the formation results of hydrogels composed of DNA were reported in 2006 (Um S.H. et al., 2006), many groups have conducted studies about the formation of gels using DNA.
- Hydrogels composed of DNA have very excellent biocompatibility, and thus are medically studied in various fields. The production results of functional DNA hydrogels that respond to heat and enzymes to induce free degradation and re-association have been recently reported (Xing Y. et al., 2011). Therefore, side effects due to overdosing of drugs can be reduced by enabling a smart drug delivery method in which drugs are allowed to flow only in case of necessity. Unlike existing hydrogel manufacturing methods using polymers, DNA hydrogels are composed of biomaterial DNA, and thus are not harmful to the human body, so the DNA hydrogels can be used as artificial tissues for wounded sites with various shapes and can be variously applied as an effective drug carrier in a medical field.
- However, nucleic acids are easily degraded by degradation enzymes existing in the human body, so that the in vivo residence of nucleic acids for application of the nucleic acids to target disease tissues is low, resulting in a lack of drug persistence, and in the case where DNA hydrogels are utilized, the degradation of the nucleic acids by degradation enzymes causes a collapse of structures, and thus the DNA hydrogels may not properly perform as roles of artificial tissues and drug carriers (Lee Jong-beom, et al., 2012). Therefore, it is necessary to conduct research to enhance the drug persistence of nucleic acids and to solve the problems of DNA hydrogels.
- The present inventors conducted continuous research in order to prepare a temperature-sensitive hydrogel, which exists in a sol state at room temperature and forms a gel when injected into the body, and as a result, the present inventors produced a temperature-sensitive hydrogel with biocompatibility and biodegradability through a combination of chitosan and a nucleic acid, and thus completed the present invention.
- Korean Patent Publication No.
2014-0090670 2014-0090670 - European Publication Patent No.
2745849 discloses a combination of polydeoxyribonucleotide (PDRN) and chitosan but does not state a temperature-sensitive hydrogel, wherein the combination contains 0.002-0.25 wt% of polydeoxyribonucleotide and 1-10 wt% of chitosan, which is different from the constitution of the present invention. - In addition,
US Patent Publication No. 2015-0111834 discloses an in-situ gel composition, wherein an anti-gelation agent is introduced for prevention of gelation at room temperature, and thus it can be seen that the in-situ gel composition is different from the constitution of the present invention. - An aspect of the present invention is to provide a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan.
- In accordance with an aspect of the present invention, there is provided a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, wherein the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1.
- Preferably, the present invention may be a temperature-sensitive hydrogel composition wherein the weight ratio of a nucleic acid and chitosan is preferably 50:1 to 2000:1 and most preferably 100:1 to 1000:1.
- The content of the nucleic acid may be 0.01 wt% to 3 wt% relative to the total weight of the composition.
- The nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
- The content of the chitosan may be 1x10-6 wt% to 0.15 wt% relative to the total weight of the composition.
- The molecular weight of the chitosan may be 3 kDa to 1000 kDa.
- Furthermore, the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient.
- The polymer material may be at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof.
- In accordance with another aspect of the present invention, there is provided a method for producing the temperature-sensitive hydrogel composition, the method including: i) preparing a nucleic acid stock solution; ii) preparing a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of a nucleic acid and chitosan is 20:1 to 10000:1, followed by stirring; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- The method may include: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and vi) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- The temperature-sensitive hydrogel composition may have an osmotic pressure of 100-500 mOsm and a pH value of 6-8.
- Hereinafter, the present invention will be described in detail.
- The temperature-sensitive hydrogel refers to a hydrogel of which a phase transition occurs from a sol into a gel or a gel into a sol according to the temperature. A transition of a sol into a gel is referred to as gelation. The gelation in the present invention is defined by a state in which a polymer having viscoelasticity forms a three-dimensional network structure with increasing temperature, and thus remains without being dissolved in a solvent.
- In the temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, the sol-gel transition temperature thereof may vary according to the mixing ratio of a nucleic acid and chitosan, and here, the sol-gel transition temperature can be adjusted by changing the mixing ratio according to the purpose for use.
- The temperature-sensitive hydrogel composition containing a nucleic acid and chitosan is highly stable in which a homogeneous state is maintained and the layer separation does not occur. The weight ratio of the nucleic acid and the chitosan is in the range of preferably 20:1 to 10000:1, more preferably 50:1 to 2000:1, and most preferably 100:1 to 1000:1.
- The content of the nucleic acid may be 0.01-3 wt%, preferably 0.1-2 wt%, and most preferably 1-1.5 wt% relative to the total weight of the composition.
- The molecular weight of the nucleic acid may be 1-100,000 kDa, preferably 10-10,000 kDa, and most preferably 50-3,500 kDa.
- The nucleic acid may be deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof. Preferably, the nucleic acid may be deoxyribonucleic acid.
- In addition, the deoxyribonucleic acid may include oligonucleotides, polynucleotides, and polydeoxyribonucleotides (PDRN).
- The nucleic acid may form a hydrogel through a combination with chitosan, and can act as a therapeutic drug in the body.
- In addition, the content of chitosan may be 1x10-6 wt% to 0.15 wt%, preferably 1x10-5 wt% to 0.1 wt%, and most preferably 1x10-4 wt% to 0.075 wt%, relative to the total weight of the composition.
- The molecular weight of chitosan is 3 kDa to 1000 kDa, but is not limited thereto.
- In addition, the temperature-sensitive hydrogel composition may contain a polymer material as an additional ingredient, wherein the polymer material may be added to make secure the adjustment of physical property changes according to the use of the temperature-sensitive hydrogel containing the nucleic acid and chitosan.
- The polymer material may employ at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof, but is not limited thereto.
- In addition, the temperature-sensitive hydrogel composition may be used for a medical use and as a cosmetic agent.
- A method for producing the temperature-sensitive hydrogel includes: i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution; ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution; iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; and iv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- The buffer solution that can be used in the preparation of the nucleic acid stock solution may employ sodium phosphate dibasic dodecahydrate, sodium chloride, magnesium chloride, potassium chloride, phosphate buffer saline, or HEPES (N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid) buffer solution, and preferably sodium phosphate dibasic dodecahydrate, but is not limited thereto.
- The acidic buffer that can be used in the preparation of the chitosan stock solution may employ acetic acid, hydrochloric acid, ascorbic acid, lactic acid, and nitric acid, and preferably acetic acid, but is not limited thereto.
- The mixing of the nucleic acid and the chitosan is conducted such that the weight ratio of nucleic acid and chitosan is 20:1 to 10000:1, and here, the content of the nucleic acid is 0.01-3 wt% relative to the total weight of the composition, and the content of the chitosan is 1x10-6 wt% to 0.15 wt% relative to the total weight of the composition.
- As for the temperature-sensitive hydrogel composition obtained by the production method, the osmotic pressure and pH thereof may be adjusted so that the composition can be injected into the human body or coated on the skin.
- For adjustment of pH of the temperature-sensitive hydrogel composition obtained by the production method, the production method may further include a step of adjusting pH in step iv).
- The osmotic pressure of the temperature-sensitive hydrogel composition obtained by the production method may be 100-500 mOsm, preferably 150-450 mOsm, and most preferably 200-400 mOsm.
- The pH of the temperature-sensitive hydrogel composition obtained by the production method may be 6-8, preferably 6.5-7.5, and most preferably 7.
- The present invention provides a temperature-sensitive hydrogel composition containing a nucleic acid and chitosan. The hydrogel has excellent biocompatibility and biostability and exhibits a sol-gel transition property according to the temperature change, so that the hydrogel exists in a sol state at room temperature, and the hydrogel is gelated when the hydrogel has a high temperature by being injected into the body or coated on the epidermal skin surface.
- Therefore, the temperature-sensitive hydrogel of the present invention can be directly injected and coated on a particular site in needed of therapy, and can increase the time for drug persistence and drug attachment through the gelation according to the temperature, and thus the drug efficacy thereof can sufficiently exerted. Therefore, the temperature-sensitive hydrogel is expected to be utilized in various therapies.
-
-
FIG. 1 shows the results of confirming physical property states of temperature-sensitive hydrogels according to the mixing ratio of a nucleic acid and chitosan. Each composition was subjected to mixing, and then was investigated for transparency and viscoelasticity (A) and precipitate generation and layer separation (B) for 3 days. -
FIG. 2 shows the results of confirming whether gels are dissolved. -
FIG. 3 shows the results of confirming the sol-gel transition of a temperature-sensitive hydrogel composition. - Hereinafter, preferable embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
- For the production of nucleic acid and chitosan hydrogels, nucleic acid and chitosan stock solutions were prepared with concentrations corresponding examples shown in table 1 below. Here, nucleic acid was put in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate, and then dissolved therein using a heat stirrer at 65Ā°C for 1 hour.
- In addition, chitosan was dissolved using 100 mM acetic acid.
- The nucleic acid and chitosan stock solutions prepared with the concentrations in table 1 below were mixed at a weight ratio of 1:1, and stirred in a heat stirrer at 60Ā°C for 1 hour. Thereafter, the temperature was lowered to room temperature, followed by stirring for 1 hour, to produce nucleic acid-chitosan hydrogels.
- Nucleic acid and chitosan stock solutions were prepared with concentrations corresponding to comparative examples shown in table 1 below. Comparative nucleic acid-chitosan hydrogels were produced by the same method as in example 1.
[Table 1] Constitution Stock solution concentration (wt%) Final concentration (wt%) Nucleic acid Chitosan Nucleic acid Chitosan Example 1-1 2 0.1 1 0.05 Example 1-2 2 0.04 1 0.02 Example 1-3 2 0.02 1 0.01 Example 1-4 2 0.002 1 0.001 Example 1-5 2 0.001 1 0.0005 Example 1-6 2 0.0004 1 0.0002 Example 1-7 2 0.0002 1 0.0001 Example 1-8 0.02 0.0002 0.01 0.0001 Example 1-9 0.02 0.00002 0.01 0.00001 Example 1-10 6 0.06 3 0.03 Example 1-11 6 0.006 3 0.003 Comparative example 1-1 2 0 1 0 Comparative example 1-2 0 0.02 0 0.01 Comparative example 1-3 2 0.2 1 0.1 Comparative example 1-4 2 0.0001 1 0.00005 - A nucleic acid-chitosan-hyaluronic acid hydrogel was produced through the following procedure.
- A nucleic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2.2 wt%. Here, the nucleic acid were dissolved using a heat stirrer at 65Ā°C for 1 hour.
- In addition, chitosan was dissolved in 100 mM acetic acid to have a concentration of 0.4 wt%.
- Sodium hyaluronic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate to have a concentration of 2 wt%. Here, the sodium hyaluronic acid was dissolved using a heat stirrer at 40Ā°C for 30 minutes, followed by cooling to room temperature with stirring using a stirrer.
- Then, 2.2 wt% of the prepared nucleic acid solution and 0.4 wt% of the prepared chitosan solution were mixed at a weight ratio of 9:1, followed by stirring in a heat stirrer at 65Ā°C for 10 minutes. 2 wt% of sodium hyaluronic acid was added to the nucleic acid-chitosan mixture solution at a weight ratio of 1:1, followed by stirring in a heat stirrer at 65Ā°C for 1 hour, and then the resulting solution was cooled to room temperature while the stirring maintained, thereby producing nucleic acid-chitosan-hyaluronic acid hydrogels of example 2.
- Chitosan and hyaluronic acid stock solutions were prepared with concentrations in table 2 below.
- Chitosan was dissolved using 100 mM acetic acid.
- Sodium hyaluronic acid was dissolved in a buffer solution of 200 mM sodium phosphate dibasic dodecahydrate. Here, sodium hyaluronic acid was dissolved using a heat stirrer at 40Ā°C for 30 minutes, and then the resulting solution was cooled to room temperature while the stirring was maintained. The prepared chitosan and hyaluronic acid solutions were mixed at a weight ratio of 1:1, followed by stirring in a heat stirrer at 65Ā°C for 1 hour. Thereafter, the temperature was lowered to room temperature, followed by stirring for 1 hour, to produce chitosan-hyaluronic acid hydrogels.
[Table 2] Constitution Stock solution concentration (wt%) Final concentration (wt%) Chitosan Hyaluronic acid Chitosan Hyaluronic acid Comparative example 2-1 0 2 0 1 Comparative example 2-2 0.02 2 0.01 1 - The hydrogel compositions of example 1, example 2, comparative example 1, and comparative example 2 were used to investigate gelation, gel stability, and solubility thereof.
- Each composition was subjected to mixing, and then the transparency and gelation state thereof were observed to the naked eye for 3 days. The gelation was examined by viscoelasticity and the gel stability was examined by precipitate generation and layer separation.
- For the solubility of gel, the hydrogel composition of each of example 1, example 2, comparative example 1, and comparative example 2 was dropped in an aqueous solution at 37.5Ā°C, followed by gelation, and then the solubility of gel was examined while the stirring was conducted at 400 rpm for 5 minutes with the temperature maintained at 37.5Ā°C. The results were shown in table 3 and
FIGS. 1 and 2 .[Table 3] Constitution Results after three days Results of stirring at 37.5Ā°C for 5 minutes Viscoelasticity Precipitate generation Layer separation Gel solubility Example 1-1 ā Ć Ć Ć Example 1-2 ā Ć Ć Ć Example 1-3 ā Ć Ć Ć Example 1-4 ā Ć Ć Ć Example 1-5 ā Ć Ć Ć Example 1-6 ā Ć Ć Ć Example 1-7 ā Ć Ć Ć Example 1-8 ā Ć Ć Ć Example 1-9 ā Ć Ć Ć Example 1-10 ā Ć Ć Ć Example 1-11 ā Ć Ć Ć Example 2 ā Ć Ć Ć Comparative Example 1-1 ā Ć Ć ā Comparative Example 1-2 Ć Ć Ć ā Comparative Example 1-3 ā ā ā ā Comparative Example 1-4 ā ā Ć ā Comparative Example 2-1 Ć Ć Ć ā Comparative Example 2-2 ā Ć Ć ā - It can be seen from table 3 and
FIG. 1 that, in the temperature-sensitive hydrogel compositions of examples 1-1 to 1-11, the precipitate isolation and the layer separation did not occur with viscoelasticity maintained, even three days after the nucleic acid and chitosan were mixed. However, as for comparative examples 1-1 to 1-4, which got out of the weight ratio range of nucleic acid and chitosan of the present invention, the precipitate generation, the layer separation, or the viscoelasticity was not observed. - In addition, it can be seen from the solubility of gel in table 3 and
FIG. 2 that the temperature-sensitive hydrogel composition of each of examples 1-1 to 1-11 formed a gel at 37.5Ā°C and the formed gel was continuously maintained, whereas comparative examples 1-1 to 1-4 were not gelated at 37.5Ā°C or were completely dissolved within 20 seconds even if the gelation occurred. - It was confirmed that, even in example 2 in which hyaluronic acid as an additional ingredient was added in the nucleic acid and chitosan, the viscoelasticity was maintained even while the precipitate isolation and the layer separation were not shown and the gel was continuously maintained after the gelation, whereas in comparative example 2-2 in which the nucleic acid was not contained, the precipitate isolation and the layer separation were not shown with viscoelasticity maintained, but the gel was dissolved within 20 seconds after the gel was formed at 37.5Ā°C (see table 3 and
FIG. 1 ). - Through these results, it can be seen that the hydrogel composition of the present invention shows temperature sensitivity, high stability, and a gel form continuously maintained after gelation, and here, it was confirmed that the weight ratio of nucleic acid and chitosan plays a key role.
- The temperature-sensitive hydrogel composition produced in each of example 1, example 2, comparative example 1, and comparative example 2 was examined for sol-gel transition.
- For the confirmation of sol-gel transition, a rheometer was used. The measurement conditions used here were PU20, gap of 0.5 mm, 0.1 Hz, and 1% stress-strain, and the changes of G' (elasticity) and G" (viscosity) were measured while the temperature was raised from 24Ā°C to 40Ā°C by 1Ā°C and then was maintained for 1 minute. In addition, the sol-gel transition after and before 36Ā°C was observed to the naked eye while the temperature of each composition was raised, and the results were shown in
FIG. 3 . - As shown in
FIG. 3 , it was observed that the temperature-sensitive hydrogel of example 1-3 exhibited a gentle decrease width of G' (elasticity) and an increase of G" (viscosity) with an increasing temperature (FIG. 3A ), which correspond to the feature of a temperature-sensitive hydrogel. In addition, it was observed that the temperature-sensitive hydrogel of example 1-3 exhibited a sol state at a temperature lower than 36Ā°C but was gelated at a temperature exceeding 36Ā°C (FIG. 3B ). It was confirmed that these results were identical in all of the temperature-sensitive hydrogel compositions in examples 1 and 2. It can be seen from these results that the hydrogel compositions of the present invention show temperature sensitivity.
Claims (13)
- A temperature-sensitive hydrogel composition containing a nucleic acid and chitosan, wherein the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1.
- The temperature-sensitive hydrogel composition of claim 1, wherein the weight ratio of the nucleic acid and the chitosan is 50:1 to 2000:1.
- The temperature-sensitive hydrogel composition of claim 2, wherein the weight ratio of the nucleic acid and the chitosan is 100:1 to 1000:1.
- The temperature-sensitive hydrogel composition of claim 1, wherein the content of the nucleic acid is 0.01 wt% to 3 wt% relative to the total weight of the composition.
- The temperature-sensitive hydrogel composition of claim 4, wherein the nucleic acid is deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or a mixture thereof.
- The temperature-sensitive hydrogel composition of claim 1, wherein the content of the chitosan is 1x10-6 wt% to 0.15 wt% relative to the total weight of the composition.
- The temperature-sensitive hydrogel composition of claim 6, wherein the molecular weight of the chitosan is 3 kDa to 1,000 kDa.
- The temperature-sensitive hydrogel composition of claim 1, wherein the temperature-sensitive hydrogel composition contains a polymer material as an additional ingredient.
- The temperature-sensitive hydrogel composition of claim 8, wherein the polymer material is at least one selected from the group consisting of hyaluronic acid, poly-Y-glutamic acid, cellulose, polyacrylic acid, polyamino acids, alginate, and derivatives and a combination thereof.
- A method for producing the temperature-sensitive hydrogel composition of any one of claims 1 to 9, the method comprising:i) preparing a nucleic acid stock solution;ii) preparing a chitosan stock solution;iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of a nucleic acid and chitosan is 20:1 to 10000:1, followed by stirring; andiv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- The method of claim 10, the method comprising:i) putting a nucleic acid in a buffer solution, and dissolving the nucleic acid in the buffer solution for 1-2 hours with stirring at 60-70Ā°C, to prepare a nucleic acid stock solution;ii) dissolving chitosan in an acidic buffer solution to prepare a chitosan stock solution;iii) mixing the nucleic acid stock solution in step i) and the chitosan stock solution in step ii) such that the weight ratio of the nucleic acid and the chitosan is 20:1 to 10000:1, followed by stirring at 55-65Ā°C for 1-2 hours; andiv) lowering the nucleic acid-chitosan mixture liquid in step iii) to room temperature with stirring.
- The method of claim 10, wherein the temperature-sensitive hydrogel composition has an osmotic pressure of 100-500 mOsm.
- The method of claim 10, wherein the temperature-sensitive hydrogel composition has a pH value of 6-8.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160015112A KR101666792B1 (en) | 2016-02-05 | 2016-02-05 | Thermosensitive hydrogel composition containing nucleic acid and chitosan |
PCT/KR2016/002013 WO2017135498A1 (en) | 2016-02-05 | 2016-02-29 | Temperature sensitive hydrogel composition including nucleic acid and chitosan |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3412313A1 true EP3412313A1 (en) | 2018-12-12 |
EP3412313A4 EP3412313A4 (en) | 2019-09-11 |
EP3412313B1 EP3412313B1 (en) | 2020-08-26 |
Family
ID=57250289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16889476.4A Active EP3412313B1 (en) | 2016-02-05 | 2016-02-29 | Temperature sensitive hydrogel composition including nucleic acid and chitosan |
Country Status (6)
Country | Link |
---|---|
US (1) | US11672756B2 (en) |
EP (1) | EP3412313B1 (en) |
JP (1) | JP6533626B2 (en) |
KR (1) | KR101666792B1 (en) |
CN (1) | CN108697805B (en) |
WO (1) | WO2017135498A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101666792B1 (en) | 2016-02-05 | 2016-10-17 | ģ£¼ģķģ¬ ķė§ė¦¬ģģ¹ķė”ėķø | Thermosensitive hydrogel composition containing nucleic acid and chitosan |
KR101916193B1 (en) * | 2016-08-25 | 2018-11-07 | ģ£¼ģķģ¬ ķė§ė¦¬ģģ¹ķė”ėķø | Injectable composition comprising nucleic acid and chitosan for articular cavity |
KR101959523B1 (en) * | 2018-01-30 | 2019-03-18 | ģ£¼ģķģ¬ ķė§ė¦¬ģģ¹ķė”ėķø | Composition comprising nucleic acids, bone graft materials and cationic polymers for bone grafting and kit for manufacturing the same |
JP7248956B2 (en) | 2018-01-31 | 2023-03-30 | äøč±ē¦ęÆåå¦ę Ŗå¼ä¼ē¤¾ | Composition, method for forming resist pattern, and method for forming insulating film |
CN109265758B (en) * | 2018-09-12 | 2020-12-04 | åäŗ¬ęäøå¤§å¦ | temperature/pH dual-response type chitin nanofiber hydrogel and preparation method thereof |
CN109810265B (en) * | 2018-12-28 | 2021-08-03 | å¤©ę“„å¤§å¦ | DNA-polysaccharide hybrid hydrogel with volume change driven by solvent and preparation method thereof |
KR102382257B1 (en) * | 2019-03-21 | 2022-04-05 | ģģ²ķ„ėķźµ ģ°ķķė „ėØ | Novel thermosensitive cellulose based hydrogel for post-surgical peritoneal adhesion prevention and preparation method thereof |
EP3733755A1 (en) | 2019-04-30 | 2020-11-04 | Universita Degli Studi di Trieste | Homogeneous hydrogels from chitosan oligosaccharide derivatives and applications thereof |
KR102100506B1 (en) * | 2019-06-27 | 2020-04-13 | ģ£¼ģķģ¬ ė©ėķ¹ | Thermosentitive chitosan hydrogel composition and bioinks composition comprising the same |
KR102258224B1 (en) | 2019-10-30 | 2021-05-31 | ģėŖ ėķźµ ģ²ģģ°ķķė „ėØ | Electrolytic Device |
KR102351107B1 (en) | 2019-12-27 | 2022-01-14 | ķźµź³¼ķźø°ģ ģ°źµ¬ģ | Hydrogel composition for pH control having antitumor effect and uses thereof |
KR102547427B1 (en) | 2020-01-22 | 2023-06-23 | ģģ²ķ„ėķźµ ģ°ķķė „ėØ | Method for producing a temperature-sensitive cellulose-based hydrogel for preventing adhesion with mitomycin C release control function |
CN111892689B (en) * | 2020-08-14 | 2023-04-25 | äøå大å¦ę蓤å¦é¢ | Nucleic acid hydrogel and preparation method thereof |
CN114259460B (en) * | 2020-09-16 | 2024-03-15 | čå·å¤§å¦ | Hydrogel composition based on immunoadjuvant and application thereof |
CN113368037B (en) * | 2021-06-15 | 2022-02-18 | åäŗ¬åå¦é¢ | Bovine lactoferrin peptide nanoparticle-loaded chitosan temperature-sensitive hydrogel and preparation method and application thereof |
CN114058033B (en) * | 2021-12-20 | 2024-06-04 | ę²³åēē§å¦é¢åä½ē“ ē ē©¶ęęéč“£ä»»å ¬åø | Preparation method of temperature-sensitive hydrogel and temperature-sensitive hydrogel product prepared by same |
CN114404358A (en) * | 2022-01-21 | 2022-04-29 | åęå¤§å¦ | Preparation method of novel injectable drug-loaded hydrogel for treating osteosarcoma |
PL443403A1 (en) | 2023-01-03 | 2024-07-08 | Politechnika GdaÅska | Hydrogel composite based on chitosan, method of producing a hydrogel composite based on chitosan and use of a composite in the form of bioink to create three-dimensional objects, especially using additive manufacturing technology, especially for the purpose of conducting cell cultures |
CN116173292B (en) * | 2023-04-19 | 2023-06-30 | åęååč”ēē©ē§ęęéå ¬åø | Preparation method of antibacterial self-adhesion moisturizing nucleotide hydrogel dressing |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1352072A4 (en) | 2001-01-17 | 2004-09-01 | Zycos Inc | Nucleic acid delivery formulations |
US8536230B2 (en) * | 2006-01-25 | 2013-09-17 | University Of Virginia Patent Foundation | Methods for regulating gelation of polysaccharide solutions and uses thereof |
EP2324045A4 (en) * | 2008-08-05 | 2013-04-03 | Univ Cornell | Photo-crosslinked nucleic acid hydrogels |
US8623403B2 (en) * | 2009-12-02 | 2014-01-07 | University Of Virginia Patent Foundation | Methods for regulating gelation of hydrogel solutions and uses thereof |
WO2012108606A1 (en) | 2011-02-08 | 2012-08-16 | ģ“ķģ¬ģėķźµ ģ°ķķė „ėØ | Sol-gel transition chitosan-polymer composite and use for same |
EP2701753B1 (en) * | 2011-04-27 | 2018-12-26 | President and Fellows of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
MX366366B (en) | 2011-11-13 | 2019-07-05 | Cresilon Inc | In-situ cross-linkable polymeric compositions and methods thereof. |
ITTO20121107A1 (en) | 2012-12-19 | 2014-06-20 | Idea Medical Devices S R L | COMPOSITION BASED ON POLYDESOSSYRIBONUCLEOTIDES AND RELATED USES |
US9757330B2 (en) | 2013-10-18 | 2017-09-12 | Industrial Technology Research Institute | Recipe for in-situ gel, and implant, drug delivery system formed thereby |
CN103848928B (en) * | 2014-01-28 | 2016-04-27 | åę¹å»ē§å¤§å¦åę¹å»é¢ | Injectable modified hyaluronic acid and preparation method thereof and composition |
KR20150111834A (en) | 2014-03-26 | 2015-10-06 | ģģ§ģ ģ ģ£¼ģķģ¬ | Mobile terminal and method for controlling the same |
FR3029790B1 (en) | 2014-12-12 | 2017-01-13 | Synolyne Pharma | CHITOSAN HYDROGEL MICROBELL |
KR101666792B1 (en) | 2016-02-05 | 2016-10-17 | ģ£¼ģķģ¬ ķė§ė¦¬ģģ¹ķė”ėķø | Thermosensitive hydrogel composition containing nucleic acid and chitosan |
-
2016
- 2016-02-05 KR KR1020160015112A patent/KR101666792B1/en active IP Right Grant
- 2016-02-29 CN CN201680080527.7A patent/CN108697805B/en active Active
- 2016-02-29 JP JP2018536253A patent/JP6533626B2/en active Active
- 2016-02-29 US US16/075,296 patent/US11672756B2/en active Active
- 2016-02-29 WO PCT/KR2016/002013 patent/WO2017135498A1/en active Application Filing
- 2016-02-29 EP EP16889476.4A patent/EP3412313B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017135498A1 (en) | 2017-08-10 |
CN108697805B (en) | 2021-07-16 |
JP2019501928A (en) | 2019-01-24 |
EP3412313A4 (en) | 2019-09-11 |
EP3412313B1 (en) | 2020-08-26 |
JP6533626B2 (en) | 2019-06-19 |
US11672756B2 (en) | 2023-06-13 |
CN108697805A (en) | 2018-10-23 |
KR101666792B1 (en) | 2016-10-17 |
US20190054015A1 (en) | 2019-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3412313B1 (en) | Temperature sensitive hydrogel composition including nucleic acid and chitosan | |
Peers et al. | Chitosan hydrogels for sustained drug delivery | |
Dragan et al. | Polysaccharides constructed hydrogels as vehicles for proteins and peptides. A review | |
Wu et al. | Chitosan-based composite hydrogels for biomedical applications | |
AU2008296975B2 (en) | Delayed self-gelling alginate systems and uses thereof | |
Wu et al. | A thermo-and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate | |
EP1753787B1 (en) | Method of covalently linking hyaluronan and chitosan | |
ES2611105T3 (en) | Three-dimensional nanocomposite materials consisting of a polysaccharide matrix and metal nanoparticles, preparation and use thereof | |
US20210015966A1 (en) | Antibacterial Cellulose Hydrogels and Preparation Method therefor | |
Vasiliu et al. | Chitosan-based polyelectrolyte complex hydrogels for biomedical applications | |
US20100279952A1 (en) | Cross-linked hydrogel containing an active substance | |
Kong et al. | The novel medical thermoresponsive hydrogel derived from chitosan | |
Siafaka et al. | Polymer Based Gels: Recent and Future Applications in Drug Delivery Field | |
Feng et al. | Natural hydrogels applied in photodynamic therapy | |
US20190184019A1 (en) | Hydrogel and preparation method thereof | |
Lee et al. | Preparation of collagen modified hyaluronan microparticles as antibiotics carrier | |
Neves et al. | Plant polysaccharides in formulation coating | |
Giri et al. | Polysaccharide Hydrogels for Drug Delivery and Regenerative Medicine | |
Debnath et al. | Hydrogels based on chitosan | |
Antony et al. | Introductory Aspects of Carboxymethyl Chitosan Derivatives | |
Nagpal et al. | Pharmaceutical Applications of Gellan Gum | |
Sun et al. | Thermosensitive injectable polysaccharide-based hydrogels: Gelation mechanisms, synthetic strategies, biomedical applications, and challenges | |
Nath et al. | Ionotropic cross-linking methods for different types of biopolymeric hydrogels | |
Hamidi et al. | An overview on current trends and future outlook of hydrogels in drug delivery. | |
Kumar et al. | Use of Polysaccharides: Novel Delivery System for Genetic Material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180801 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602016042991 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0047360000 Ipc: A61K0009080000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190813 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/08 20060101AFI20190807BHEP Ipc: A61K 31/7088 20060101ALI20190807BHEP Ipc: A61K 47/36 20060101ALI20190807BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200331 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016042991 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1305674 Country of ref document: AT Kind code of ref document: T Effective date: 20200915 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201126 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201228 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201126 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201127 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20200826 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1305674 Country of ref document: AT Kind code of ref document: T Effective date: 20200826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201226 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016042991 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210228 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240222 Year of fee payment: 9 Ref country code: GB Payment date: 20240222 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240229 Year of fee payment: 9 Ref country code: FR Payment date: 20240221 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200826 |